p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy
Clinical cancer research : an official journal of the American Association for Cancer Research | 6 Jan 2018
NR Hardwick, P Frankel, C Ruel, J Kilpatrick, W Tsai, F Kos, TI Kaltcheva, L Leong, R Morgan, V Chung, R Tinsley, M Eng, SP Wilczynski, JDI Ellenhorn, DJ Diamond and M Cristea
To conduct a Phase I trial of a Modified Vaccinia Ankara vaccine delivering wild type human p53 (p53MVA) in combination with gemcitabine chemotherapy in patients with platinum-resistant ovarian cancer.
* Data courtesy of Altmetric.com